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Abstract: Breast cancer is a significant cause of death in women. Estrogen receptor (ER) and progesterone receptor 
(PR) are important prognostic factors indicating higher recovery rate in the breast cancer patients. Currently, im-
munohistochemical (IHC) staining is a conventional method to identify expression of ER and PR. If a breast cancer 
patient expresses ER or PR, a chemotherapy with estrogen inhibitors such as tamoxifen is supposed to be effec-
tive. Although IHC staining is a reliable method, it may not a useful method for continuous monitoring of ER and PR 
expression changes in multiple breast cancer patients. In the present study, we evaluated an alternative method of 
IHC for detection of ER and PR expression. A quantitative RT-PCR method called ‘the BrightGen HR RT-qDx assay’ 
was employed to detect mRNA expression of the nuclear receptors in 199 formalin-fixed paraffin-embedded (FFPE) 
breast cancer tissue samples. Among the ER/PR positive samples by IHC, 83 were determined positive and 16 were 
determined negative for the nuclear receptor mRNA by the quantitative RT-PCR method. Among the ER/PR negative 
samples by IHC, 37 were determined negative and 2 were determined positive by the quantitative RT-PCR method. 
The overall sensitivity and specificity of the quantitative RT-PCR method were 83.8% and 94.8% (P = 0.0026), re-
spectively. We also optimized the quantitative RT-PCR method by setting up the diagnostic cut-off value using the 
likelihood ratio. The highest likelihood ratio was when the expression levels of the relative nuclear receptor mRNA 
passed 103.3 at which sensitivity and specificity was highest. These data suggest that BrightGen HR RT-qDx assay 
could be an alternative method for detection of the prognostic factors of nuclear receptors expressed in breast can-
cer patients for providing essential information for therapeutic application of tamoxifen. 
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Introduction
Breast cancer is the most diagnosed and the 
second leading cause of cancer deaths for 
women, occurring in about 300,000 and killing 
about 40,000 women a year [1]. A substantial 
body of epidemiological, experimental and clini-
cal evidence has indicated that treatment of 
breast cancer epithelial cells with estrogen 
induced progression of breast cancers [2]. 
Breast cancer is often considered a systemic 
disease because even the early tumor cells dis-
seminate [2]. Therefore, pathological outcome 
of breast cancer is largely dependent on the 
metastases of early tumor cells. Estrogen 
receptor (ER) and progesterone receptor (PR) 
are regarded as prognostic and predictive fac-
tors of breast cancer [3]. ER and PR are mem-
bers of nuclear receptors, of which activities 
are regulated by small hydrophobic molecules 
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agonist and antagonist [4]. ER regulates expres-
sion of a variety of genes involved in cell growth, 
so that it plays a critical role in the growth of 
breast cancer [4]. Because of that reasons, 
expression of the ER has become an important 
biomarker for pathogenesis and maintenance 
of breast cancer. Approximately 70% of breast 
tumors express the ER [5, 6] and endocrine 
therapies, such as the anti-estrogen tamoxifen, 
are the most common and effective therapies 
for patients with ER-positive breast cancer. 
Thus, ER is the single most important prognos-
tic and predictive factor determining treatment 
outcomes [7, 8]. PR also plays significant roles 
in breast cancer biology. PR, an estrogen-regu-
lated gene, is often co-expressed with ER, and 
independently predicts breast cancer out-
comes, and has been implicated in regulating 
stem-like cancer cells [9].
Tamoxifen, raloxifene, and fulvestrant are 
selective ER modulators (SERMs) that are 
important therapeutic agents for women with 
endocrine-sensitive (ER-positive) breast cancer 
because SERMs can effectively antagonize the 
proliferation-inducing effects of estrogen. The 
estrogen effect also can be antagonized by 
inhibitors of aromatase, which is an enzyme for 
estrogen generation, such as anastrozole and 
letrozole. The detection of ER and PR by immu-
nohistochemistry (IHC) is not a decisive prog-
nostic marker for breast cancer, but it is essen-
tial marker indicating susceptibility for endo- 
crine therapy with SERMs [10]. To detect ER 
and PR in cancer tissues, IHC has been widely 
used [11]. IHC gives robust signals for many 
biomarkers, however, the intensity of IHC 
depends on the enzyme activity of horseradish 
peroxidase (HRP), which is conjugated on anti-
bodies. Therefore, the staining intensity is sig-
nificantly influenced by reaction time, tempera-
ture, and HRP substrate concentrations which 
are often vary depending on the extent of train-
ing of experimenters. Despite the international 
been proposed [13]. In the present study, the 
quantitative RT-PCR method was employed for 
quantification of ER and PR expression in 199 
formalin-fixed paraffin-embedded (FFPE) tissue 
samples from breast cancer patients. We used 
a commercial kit called ‘BrightGen HR RT-qDx’ 
that uses one-tube nested RT-PCR process. 
Through the experiments, we evaluated wheth-
er the quantitative RT-PCR (RT-qPCR) method 
can be a reliable alternative method of current 
IHC method for detection of ER and PR in clini-
cal tissue samples.
Materials and methods
Clinical samples
For this study, we selected a total of 199 forma-
lin-fixed paraffin-embedded (FFPE) tissue sam-
ples obtained from patients diagnosed breast 
cancer at Yonsei University Severance Hospital 
(Seoul, Republic of Korea) for 2 years. These 
tissue samples have been confirmed the ex- 
pression of ER, PR, and HER2 with IHC method. 
All subjects were provided with a written in- 
formed consent and the study was approved by 
the Institutional Ethics Committee of Yonsei 
University Severance Hospital (approval num-
ber 1-2010-0018).
Cell lines and cell culture
Human breast carcinoma cell line MCF7, which 
over-expresses ER and PR, and MDA-MB-231, 
which weakly expresses ER and PR, were kindly 
provided by the Yonsei University Cancer Center 
(Seoul, Republic of Korea). The THP-1 human 
monocytic cell line, which over-expresses ER, 
was kindly provided by Yonsei University College 
of Medicine (Seoul, Republic of Korea). The 
SK-BR3, MCF7, and MDA-MB-231 cancer cells 
were maintained as mono-layer cultures in 
DMEM at 37°C, 5% CO2. THP-1 cells were cul-
tured in RPMI 1640 supplemented with 2 mM 
Table 1. Relative NR mRNA expression levels detected by NR 
mRNA RT-qPCR in various cell lines
Cell line NR (ER/PR) status Origin of cell Relative NR mRNA expression level
SK-BR-3 Weak-expressing Breast cancer 3.66 ± 1.34
MCF-7 Over-expressing Breast cancer 92.78 ± 7.42
MDA-MB-231 Weak-expressing Breast cancer 1
THP-1 Over-expressing Monocyte 52.16 ± 4.2.
efforts to standardize the cut-offs 
and the method of IHC staining, a 
complete standardization for 
assessment of ER and PR with 
IHC is still challenging owing to 
the inherent semi-quantitative 
nature of the technology [12, 13].
As an alternative of the IHC assay, 
a quantitative RT-PCR method 
targeting mRNA of ER and PR has 
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glutamine. All of the media was supplemented 
with 10% fetal bovine serum (FBS), 100 U/mL 
of penicillin, and 100 μg/mL of streptomycin 
(Gibco-BRL, Carlsbad, California, USA).
Deparaffinization and RNA isolation from the 
FFPE breast cancer tissues 
In order to remove paraffin from FFPE tissue 
samples, two pieces of 10-µm-thick FFPE 
breast cancer tissue sections were put in a 1.5-
mL microcentrifuge tube, to which 1 mL of 
100% xylene was added. After shaking and vor-
texing, the tube was heated for 5 min at 50°C 
to melt the paraffin and centrifuged for 2 min at 
room temperature at 20,000 x g to precipitate 
the tissue. The xylene supernatant was 
removed, and 1 mL of 100% EtOH was added to 
the pellet. After mix with EtOH, the tube was 
centrifuged at 20,000 x g for 2 min at room 
temperature, and then the EtOH was removed 
total RNA were determined by measuring the 
absorbance at 260 nm and 280 nm using the 
Infinite 200® spectrophotometer (Tecan, Salz- 
burg, Austria). All steps in the preparation and 
handling of total RNA was conducted in a lami-
nar flow hood under RNase-free conditions. 
The isolated total RNA was stored at -70°C until 
used for cDNA synthesis.
cDNA synthesis
Complementary DNA (cDNA) was synthesized 
using an M-MLV Reverse Transcriptase kit 
(Invitrogen, Carlsbad, CA, USA) and random 
hexamers (Invitrogen) according to the manu-
facturer’s protocols. Briefly, 10 μL of total RNA 
was added to the master mix containing 1 μL of 
10 mM dNTP mix (10 mM each dATP, dGTP, 
dCTP, and dTTP at a neutral pH), 0.25 ug of ran-
dom hexamers, and 5 μL of DEPC-treated water 
in a PCR tube. The reaction mixture was incu-
Figure 1. The analytical sensitivity of HR mRNA RT-qPCR. A. The analyti-
cal sensitivity of HR mRNA RT-qPCR was determined using serially diluted 
breast cancer cell line MCF7, an ER and PR over-expressing cell line. B. 
HR mRNA RT-qPCR was performed three times and the mean Ct value was 
calculated (N.D.: Not detected).
without disturbing the pellet. 
The ethanol washing repeated 
twice. Residual EtOH was re- 
moved as much as possible 
without disturbing the pellet, 
and the pellet was dried in the 
air for 25 min.
A total RNA isolation kit, ‘Ma- 
gNA Pure LC RNA Isolation Kit 
III-Tissue’ (Roche Diagnostics, 
Mannheim and Penzberg, Ger- 
many), was used according to 
the manufacturer’s protocol 
for total RNA extraction. In 
brief, 140 μL of tissue homog-
enized buffer (Roche Diagno- 
stics, Ma-nnheim and Penz-
berg, Germa-ny) and 16 μL of 
10% SDS solution were added 
to the deparaffinized tissue, 
sequentially. Then, the mixed 
samples were vortexed and 
incubated overnight at 55°C, 
after which 220 μL of tissue 
lysis buffer (Roche Diagnos- 
tics) was added to the tissue 
lysate supernatant. Then, Mag- 
NA Pure LC 2.0 (Roche Diag- 
nostics, Mannheim and Penz- 
berg, Germany) machine was 
used to prepare total RNA. The 
purity and concentration of 
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bated at 65°C for 5 min, and then quickly 
chilled on ice. A mixture of 4 μL of 5 × first-
strand buffer, 2 μL of 0.1 M dithiothreitol (DTT), 
and 1 μL of M-MLV reverse transcriptase (RT) 
was added to the PCR tube. cDNA synthesis 
reaction was performed at 25°C for 10 min, 
37°C for 50 min, and 70°C for 15 min. 
RT-qPCR assay for the nuclear receptor detec-
tion
The relative mRNA expression levels of the 
nuclear receptors (NRs), ER and PR, were mea-
sured by a RT-qPCR employing TaqMan probes 
using a CFX-96 real-time PCR system (Bio-Rad, 
Figure 2. Comparison of ROC curves of NR 
mRNA RT-qPCR results according to the differ-
ent Ct value of GAPDH. For ROC analysis, the 
NR mRNA expression levels by RT-qPCR and 
NR IHC results (NR IHC-positive and -nega-
tive) were used. The ROC curve obtained by 
samples with GAPDH Ct values below 30 (C) 
had the most significant AUC and p-value 
(AUC = 0.9267, P < 0.0001) compared with 
all GAPDH Ct values (A) (AUC = 0.8365, P < 
0.0001) and GAPDH Ct value below 33 (B) 
(AUC = 0.8732, P < 0.0001). GAPDH Ct values 
were determined according to GAPDH mRNA 
RT-qPCR.
Table 2. Clinical cut-off values of NR mRNA RT-qPCR obtained by ROC curve analysis with GAPDH Ct 
value below 30
Relative NR mRNA expression 
level Sensitivity % 95% CI Specificity % 95% CI Likelihood ratio
> 96.4 81.2 72.2% to 88.3% 92.3 79.1% to 98.4% 10.6
> 98.4 80.2 71.1% to 87.5% 92.3 79.1% to 98.4% 10.4
> 103.3 80.2 71.1% to 87.5% 94.9 82.7% to 99.4% 15.6
> 107.3 79.2 70.0% to 86.6% 94.9 82.7% to 99.4% 15.5
Abbreviations: ROC, Receiver operating characteristic; CI, Confidence interval.
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Hercules, CA, USA), which was used for thermo-
cycling and fluorescence detection. The RT- 
qPCR TaqMan assay was carried out with the 
‘BrightGen HR RT-qDX assay kit’ (Syantra, 
Calgary, Canada) according to the manufactur-
er’s protocols. Real-time PCR amplification for 
HER2 mRNA was performed using a total vol-
ume of 20 μL which was composed of 10 μL of 
2 × Thunderbird probe qPCR mix (Toyobo, 
Osaka, Japan), 5 μL of primer and TaqMan 
probe mixture, 2 μL of template cDNA, and D.W. 
for each sample. Positive and negative controls 
were included throughout the procedure. 
No-template controls with sterile D.W. instead 
of template DNA were incorporated into each 
run under the following conditions: 95°C for 3 
min, followed first by 10 cycles of 15 sec at 
95°C and 30 sec at 60°C, then 40 cycles of 15 
sec at 95°C and 30 sec at 55°C. The mRNA 
expression level was quantified by determining 
the cycle threshold (CT), which is the number of 
PCR cycles required for the fluorescence to 
exceed a value significantly higher than the 
background fluorescence. To avoid false nega-
tives due to degradation of mRNA, a GAPDH 
reference gene was used as a control. Target 
gene mRNA expression levels relative to GAPDH 
were automatically calculated using the com-
parative Ct method by CFX Manager Software 
v1.6 (Bio-Rad) or GenexSoftware (Bio-Rad), 
and the cut-off values for distinguishing bet- 
ween positive and negative results was the rel-
ative NR mRNA expression level of 103.3. 
Statistical analysis
For statistical data analysis, ‘GraphPad PRISM 
5’ software (GraphPad, La Jolla, CA, USA) was 
used. In order to determine statistical signifi-
cance of the data, student’s t-test and one-way 
ANOVA were carried out for the two-group com-
parison and multiple-group comparison, respe- 
ctively. Receiver operating characteristic (ROC) 
curve analysis was applied to all the data of the 
NRs detection by IHC and RT-qPCR. 
Results
Analytical sensitivity of the RT-qPCR for the 
NRs detection in breast cancer cell lines
In order to test whether the BrightGen HR 
RT-qDx used in this study was able to detect 
the NRs mRNA quantitatively, cDNA of breast 
cancer cell MCF7, which expresses high levels 
of ER and PR mRNA, was 10-fold diluted seri-
ally from 1 × 105 cells/mL to 1 cell/mL. The 
RT-qPCR for the NRs mRNA was performed 
three times. The mean Ct values of RT-qPCR 
using 105, 104, 103, 102, 10, and 1 cells/mL 
were 16.96, 20.09, 24.44, 28.26, and 34.89, 
respectively. The Ct value from the blank con-
trol reaction did not show any signal in any of 
the experiments (Figure 1).
Data were expressed as relative expression of 
the NRs to that in a calibrator cell line, MDA-
MB-231. Expression levels of the NRs in MDA-
MB-231 were set to 1X expression because 
MDA-MB-231 has low expression of ER and PR. 
Therefore, all the analyzed NR expression level 
was exhibited as fold increases toward the 
expression levels in the calibrator cell line. Two 
cell lines, MCF7 and THP-1, were employed as 
another control cell lines because they express 
higher level of the NRs: MCF7 expresses 
93-fold higher and THP-1 expresses 52-fold 
Figure 3. Evaluation of NR mRNA RT-qPCR accord-
ing to the NR IHC score. FFPE breast cancer tissue 
samples were grouped by NR IHC results. The p-val-
ues for NR IHC-negative and -positive samples were 
calculated using Student’s t-test (P = 0.0026).
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higher expression level of the NRs than that in 
MDA-MB-231 cell line, respectively (Table 1).
The range of relative expression level of the 
NRs, and diagnostic cut-off determination of 
the RT-qPCR assay
Relative expression level of the NRs in the FFPE 
samples detected negative with IHC for the 
ous results (Figure 3). The samples were classi-
fied into two groups according to the NRs IHC 
results. The NRs-positive samples included 
over 10 samples having ER-positive. PR status 
was also used: IHC PR-positive status was over 
10 cases. Of the NRs-positive IHC results, 83 
samples were decided positive and 16 cases 
were decided negative by the RT-qPCR analy-
ses. Among the samples IHC NR-negative, 37 
Table 3. Comparison of NR mRNA RT-qPCR results with NR 
IHC results
NR IHC status
NR mRNA RT-qPCR No. of samples (%)
Total
Positive Negative
NR positive 83 (83.8) 16 (16.2) 99 (100)
NR negative 2 (5.1) 37 (94.9) 39 (100)
Total 93 (67.4) 47 (32.6) 138 (100)
Figure 4. Correlation coefficient analysis between the relative NR 
mRNA RT-qPCR and NR IHC results. The correlation between NR 
mRNA RT-qPCR and NR IHC results indicate a relationship (Pearson r 
= 0.4384, r2 = 0.1922, P < 0.0001).
NRs ranged from 0.001 to 626 (aver-
age, 216.9), and IHC-positive FFPE 
samples ranged from 1.4 to 4705 
(average, 1136.7). 
ROC curve analyses and patients’ 
IHC results were also used in order 
to determine the optimal cut-off 
value of the RT-qPCR assay for 
detection of the NRs in clinical sam-
ples. For the analysis, patients were 
divided into two groups: IHC-positive 
and IHC-negatives for the NRs. The 
IHC-positive group contained FFPE 
samples having IHC scores greater 
than 10% of ER and/or PR, whereas 
IHC-negative group contained IHC 
scores less than 10% of ER and PR 
results. 
Area under the curve (AUC) obtained 
using the samples with any GAPDH 
Ct values (Figure 2A) was 0.8365, 
while AUC of the samples with 
GAPDH Ct values below 33 (Figure 
2B) was 0.8732. AUC of the samples 
with GAPDH Ct values below 30 
(Figure 2C) showed the highest score 
(AUC = 0.9259) indicating the high-
est sensitivity and specificity. The 
cut-off value of the RT-qPCR was 
determined by the likelihood ratio. 
The highest likelihood ratio was the 
relative NRs mRNA levels over 103.3 
that had the highest sensitivity and 
specificity. Based on this result, 
samples having a relative NRs mRNA 
expression level greater than 103.3 
by the RT-qPCR assay were consid-
ered positive in this study (Table 2).
Comparison between the RT-qPCR 
and IHC for detection of the NRs
The relative NRs mRNA levels in the 
FFPE samples were determined pos-
itive or negative using the clinical 
cut-off value obtained from the previ-
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were decided negative and two were decided 
positive by the RT-qPCR. The overall sensitivity 
and specificity of the the RT-qPCR for the NRs 
were 83.8% and 94.8%, respectively (Table 3). 
The p-values for the NRs IHC-negative and 
-positive samples were calculated using 
Student’s t-test to be statically significant (P = 
0.0026).
Correlation of the relative NRs mRNA expres-
sion levels with the NRs IHC scores
In order to verify the correlation between rela-
tive NRs mRNA expression levels and NRs IHC 
scores, correlation coefficient analysis was per-
formed using the clinical samples having 
GAPDH Ct value below 30, depending on the 
results of the ROC curve analysis (Figure 4).
Samples having NR IHC score of below 10 
showed 35, samples having NR IHC score of 10 
to 50 showed 10, samples having NR IHC score 
of 60 showed 5, samples having NR IHC score 
of 70 showed 7, samples having NR IHC score 
of 80 showed 12, samples having NR IHC score 
of 90 showed 44, and samples having NR IHC 
score of 100 showed 19. Then, these NR IHC 
results were compared with the results 
obtained from the NR mRNA RT-qPCR analy-
ses. The correlation coefficient analysis data 
revealed that there was a correlation between 
the results for the NRs expression by the 
RT-qPCR and standard IHC test (Pearson r = 
0.4384, r2 = 0.1922, P < 0.0001) (Figure 4).
Discussion
IHC is a standard method to detect expression 
of ER and PR in clinical samples for determining 
therapeutic application of Tamoxifen to breast 
cancer patients. IHC analysis also can be used 
for screening, diagnosis, and determination of 
cancer stage. Nevertheless, there are un- 
changeable weaknesses in IHC: time-consum-
ing, inconsistent results between laboratories, 
and large dependency on antibodies used in 
the process [14, 15]. To complement the IHC 
analysis, we evaluated e a RT-qPCR assay as 
an alternative standard method for quantifica-
tion of the NRs mRNA expression. RT-qPCR is 
considered a reliable method for quantification 
of mRNA expression recommended by the 
Clinical and Laboratory Standards Institute 
(CLSI, USA) guidelines. High sensitivity and 
specificity are usually achieved with the RT- 
qPCR because primers and probes can be 
designed gene sequence-specific [16]. There- 
fore, we employed a RT-qPCR method for ana-
lyzing the NRs expression in the FFPE breast 
cancer tissue samples. Another strong point of 
the RT-qPCR might be involvement of an inter-
nal control: the NRs mRNA expression level was 
a relative fold increase toward the expression 
level of housekeeping gene, GAPDH. 
The BrightGen HR RT-qDx assay kit used in this 
study is based on one-tube nested RT-qPCR. 
The one-tube nested RT-qPCR was known to 
approximately 100 times more sensitive than 
conventional qPCR [17]. Additionally, it has 
advantages of low risk of cross-contamination 
and less laborious procedure because all the 
sequential reactions are done in a single closed 
tube [17]. Actually, 83/99 (83.8%) samples 
were determined positive by BrightGen HR 
RT-qDx assay in our study (Table 3), which is 
higher than the 56/99 (56.6%) positivity deter-
mined by a conventional RT-PCR [18]. Thus, 
BrightGen HR RT-qDx kit, which based on one-
tube nested RT-qPCR, was more sensitive than 
conventional qPCR for quantification of the NRs 
expression. Successful application of this RT- 
qPCR assay for clinical samples was evaluated 
using a total number of 138 FFPE tissue sam-
ples from breast cancer patients. Extra- 
ction of a high-quality and high-quantity of RNA 
from FFPE tissue samples is essential to obtain 
reliable results with RT-qPCR methods [19-21]. 
The quality and quantity of RNAs extracted 
from FFPE tissues were monitored by measur-
ing Ct values of a housekeeping gene. Only 
when the RNA specimens met the criteria of 
quality and quantity, we used them for the anal-
yses. In this study, RNAs having Ct values of 
GAPDH below 30 were used (Table 2). The sen-
sitivity and specificity of the RT-qPCR for the 
NRs were 80.2% and 94.8%, respectively 
(Figure 3 and Table 3). The discrepancy be- 
tween the results obtained by the RT-qPCR and 
the IHC may be due to the low sensitivity of the 
RT-qPCR for the FFPE-derived RNA samples or 
false positivity of the IHC analyses. Further 
evaluation with larger number of FFPE breast 
cancer tissue specimens from various clinical 
fields is required to analyze the gap between 
the two assays. 
In conclusion, this study shows that as long as 
good quality RNA is obtained from the stored 
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tumor tissues, the RT-qPCR method might be 
able to replace conventional IHC analysis for 
detection and quantification of ER and PR 
because the RT-qPCR method revealed high 
correlation with IHC for detection of the NRs in 
the clinical samples. Since many new biomark-
ers are being developed, we expect that the 
RT-qPCR can be applied to quantification of the 
biomarkers as a conventional analysis with 
high reproducibility and cost-efficiency 
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